CISPLATIN-INDUCED VOMITING DEPENDS ON CIRCADIAN TIMING
- 1 January 2001
- journal article
- clinical trial
- Published by Taylor & Francis in Chronobiology International
- Vol. 18 (5) , 851-863
- https://doi.org/10.1081/cbi-100107520
Abstract
We examined whether the clock time of cisplatin plus antiemetic and diuretic administration affects the amount of cisplatin-associated emesis and severity of renal toxicity. We treated 22 patients with urogenital cancer with two courses of chemotherapy containing 70 mg/m2 of cisplatin. Cisplatin together with furosemide was administered in the morning (05:00) or evening (17:00) during two courses 1 month apart in a crossover fashion. Ondansetron was given either before or after cisplatin to control nausea and vomiting. The number of vomiting episodes, serum creatinine, serum urea nitrogen (BUN), creatinine clearance, and urinary β-N-acetyl glucosamidase (NAG) concentration were evaluated before and after each treatment course. Regardless of the timing of ondansetron, morning compared to evening cisplatin was always associated with greater vomiting in the first treatment course. However, prophylactic administration of ondansetron markedly diminished the impact of the clock time of cisplatin administration. Serum creatinine transiently decreased rather than increased 14 days after cisplatin and furosemide administration, while NAG excretion increased 3 days after cisplatin and furosemide administration. In the first course, serum creatinine levels were similar regardless of the clock time of cisplatin and furosemide administration. However, in the second course, serum creatinine rose in patients given evening cisplatin and furosemide, while it remained unchanged in those given morning cisplatin and furosemide. Moreover, the first course morning cisplatin and furosemide treatment was associated with less change in NAG excretion (less kidney toxicity) than the first course of evening cisplatin and furosemide treatment. The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course. The clock time of cisplatin administration had an impact on the frequency of emesis. Prophylactic ondansetron, however, diminished the time-of-day dependency of cisplatin-induced vomiting. Administration of cisplatin and furosemide in the morning rather than evening appears to cause less renal damage, and this damage may be further reduced with aggressive hydration and routine administration of furosemide. (Chronobiology International, 18(5), 851–863, 2001)Keywords
This publication has 17 references indexed in Scilit:
- Sleep protects against chemotherapy induced emesisCancer, 1996
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Antiemetic properties of the 5HT3-receptor antagonist, gr38032fCancer Treatment Reviews, 1987
- 5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesisNeuropharmacology, 1986
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy.Journal of Clinical Oncology, 1986
- Lack of antiemetic effect of high-dose metoclopramide.Journal of Clinical Oncology, 1985
- Circadian Timing of Cancer ChemotherapyScience, 1985
- Nausea and Vomiting as Major Complications of Cancer ChemotherapyDrugs, 1983
- Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatmentCancer, 1979